ProfileGDS5678 / 1417680_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 41% 47% 45% 45% 47% 45% 45% 44% 46% 73% 67% 73% 74% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9868841
GSM967853U87-EV human glioblastoma xenograft - Control 23.0932147
GSM967854U87-EV human glioblastoma xenograft - Control 33.0591745
GSM967855U87-EV human glioblastoma xenograft - Control 42.990145
GSM967856U87-EV human glioblastoma xenograft - Control 53.0492747
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1413945
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1089745
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0271744
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0534246
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.7210973
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.067667
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.6721673
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.7678274
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1472168